104 related articles for article (PubMed ID: 37949475)
21. Identification of prognosis-related cyclin-dependent kinases and potential response drugs in hepatocellular carcinoma.
Chen S; Shen B; Wu Y; Shen L; Qi H; Cao F; Huang T; Tan H; Zhang G; Fan W
J Cancer Res Ther; 2023 Feb; 19(1):108-116. PubMed ID: 37006050
[TBL] [Abstract][Full Text] [Related]
22. Cyclin-dependent kinase 1 as a potential target for lycorine against hepatocellular carcinoma.
Yin S; Yang S; Luo Y; Lu J; Hu G; Wang K; Shao Y; Zhou S; Koo S; Qiu Y; Wang T; Yu H
Biochem Pharmacol; 2021 Nov; 193():114806. PubMed ID: 34673013
[TBL] [Abstract][Full Text] [Related]
23. Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma.
Shen B; Zhang G; Liu Y; Wang J; Jiang J
Genes (Basel); 2022 Oct; 13(10):. PubMed ID: 36292719
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of biological networks and the eukaryotic initiation factor 4A-3 gene as pivotal in hepatocellular carcinoma.
Lin Y; Liang R; Mao Y; Ye J; Mai R; Gao X; Liu Z; Wainwright T; Li Q; Luo M; Ge L; Li Y; Zou D
J Cell Biochem; 2020 Oct; 121(10):4094-4107. PubMed ID: 31898336
[TBL] [Abstract][Full Text] [Related]
25. Identification of Multiple Hub Genes and Pathways in Hepatocellular Carcinoma: A Bioinformatics Analysis.
Liu J; Han F; Ding J; Liang X; Liu J; Huang D; Zhang C
Biomed Res Int; 2021; 2021():8849415. PubMed ID: 34337056
[TBL] [Abstract][Full Text] [Related]
26. HSP90AB1 Promotes the Proliferation, Migration, and Glycolysis of Head and Neck Squamous Cell Carcinoma.
Zhang H; Yin X; Zhang X; Zhou M; Xu W; Wei Z; Song C; Han S; Han W
Technol Cancer Res Treat; 2022; 21():15330338221118202. PubMed ID: 35929142
[No Abstract] [Full Text] [Related]
27. Significance of Identifying Key Genes Involved in HBV-Related Hepatocellular Carcinoma for Primary Care Surveillance of Patients with Cirrhosis.
Li Y; Li J; He T; Song Y; Wu J; Wang B
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553600
[TBL] [Abstract][Full Text] [Related]
28. Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis.
Zhou Z; Li Y; Hao H; Wang Y; Zhou Z; Wang Z; Chu X
Cell Transplant; 2019 Dec; 28(1_suppl):76S-86S. PubMed ID: 31822116
[TBL] [Abstract][Full Text] [Related]
29. Prognostic, Immunological, and Mutational Analysis of MTA2 in Pan-Cancer and Drug Screening for Hepatocellular Carcinoma.
Huang X; Tan J; Chen M; Zheng W; Zou S; Ye X; Li Y; Wu M
Biomolecules; 2023 May; 13(6):. PubMed ID: 37371463
[TBL] [Abstract][Full Text] [Related]
30. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
31. Identification and validation of real hub genes in hepatocellular carcinoma based on weighted gene co-expression network analysis.
Qiao Y; Yuan F; Wang X; Hu J; Mao Y; Zhao Z
Cancer Biomark; 2022; 35(2):227-243. PubMed ID: 36120772
[TBL] [Abstract][Full Text] [Related]
32. Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma.
Wei ZL; Zhou X; Lan CL; Huang HS; Liao XW; Mo ST; Wei YG; Peng T
BMC Gastroenterol; 2022 Feb; 22(1):77. PubMed ID: 35193513
[TBL] [Abstract][Full Text] [Related]
33. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
34. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma.
Wang Z; Zhu J; Liu Y; Liu C; Wang W; Chen F; Ma L
J Transl Med; 2020 Feb; 18(1):67. PubMed ID: 32046766
[TBL] [Abstract][Full Text] [Related]
35. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
Xu Q; Tu J; Dou C; Zhang J; Yang L; Liu X; Lei K; Liu Z; Wang Y; Li L; Bao H; Wang J; Tu K
Mol Cancer; 2017 Dec; 16(1):178. PubMed ID: 29262861
[TBL] [Abstract][Full Text] [Related]
36. LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway.
Bao J; Chen X; Hou Y; Kang G; Li Q; Xu Y
Biomed Pharmacother; 2018 Nov; 107():824-833. PubMed ID: 30142544
[TBL] [Abstract][Full Text] [Related]
37. miR-195-5p Targets CDK1 To Regulate New DNA Synthesis and Inhibit the Proliferation of Hepatocellular Carcinoma Cells.
Zhou C; Zhu S; Li H
Appl Biochem Biotechnol; 2023 May; 195(5):3477-3490. PubMed ID: 36607481
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive analysis of an immune-related ceRNA network in identifying a novel lncRNA signature as a prognostic biomarker for hepatocellular carcinoma.
Chen R; Chen Y; Huang W; Zhao Y; Luo W; Lin J; Wang Z; Yang J
Aging (Albany NY); 2021 Jul; 13(13):17607-17628. PubMed ID: 34237706
[TBL] [Abstract][Full Text] [Related]
39. The Effect of the Histone Chaperones HSPA8 and DEK on Tumor Immunity in Hepatocellular Carcinoma.
Yang C; Shao Y; Wang X; Wang J; Wang P; Huang C; Wang W; Wang J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768989
[TBL] [Abstract][Full Text] [Related]
40. A systematic study on the treatment of hepatitis B-related hepatocellular carcinoma with drugs based on bioinformatics and key target reverse network pharmacology and experimental verification.
Li S; Hao L; Hu X; Li L
Infect Agent Cancer; 2023 Jul; 18(1):41. PubMed ID: 37393234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
